A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance

Bingsen Zhou, Leila Su, Shuya Hu, Weidong Hu, M. L Richard Yip, Jun Wu, Shikha Gaur, D. Lynne Smith, Yate Ching Yuan, Timothy W. Synold, David Horne, Yun Yen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A novel ligand-binding pocket on the RNR small subunit (RRM2) near the C-terminal tail was proposed by computer modeling and verified by site-directed mutagenesis and nuclear magnetic resonance (NMR) techniques. A compound targeting this pocket was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule database. By lead optimization, we developed the novel RNR inhibitor COH29 that acted as a potent inhibitor of both recombinant and cellular human RNR enzymes. COH29 overcame hydroxyurea and gemcitabine resistance in cancer cells. It effectively inhibited proliferation of most cell lines in the NCI 60 human cancer panel, most notably ovarian cancer and leukemia, but exerted little effect on normal fibroblasts or endothelial cells. In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle. Site-directed mutagenesis, NMR, and surface plasmon resonance biosensor studies confirmed COH29 binding to the proposed ligand-binding pocket and offered evidence for assembly blockade of the RRM1-RRM2 quaternary structure. Our findings offer preclinical validation of COH29 as a promising new class of RNR inhibitors with a new mechanism of inhibition, with broad potential for improved treatment of human cancer.

Original languageEnglish
Pages (from-to)6484-6493
Number of pages10
JournalCancer Research
Volume73
Issue number21
DOIs
Publication statusPublished - Nov 1 2013
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Holoenzymes
Drug Resistance
Growth
Neoplasms
National Cancer Institute (U.S.)
gemcitabine
Site-Directed Mutagenesis
Magnetic Resonance Spectroscopy
Ligands
Hydroxyurea
Surface Plasmon Resonance
Biosensing Techniques
Heterografts
Antineoplastic Agents
Ovarian Neoplasms
Half-Life
Tail
Leukemia
Iron

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. / Zhou, Bingsen; Su, Leila; Hu, Shuya; Hu, Weidong; Yip, M. L Richard; Wu, Jun; Gaur, Shikha; Smith, D. Lynne; Yuan, Yate Ching; Synold, Timothy W.; Horne, David; Yen, Yun.

In: Cancer Research, Vol. 73, No. 21, 01.11.2013, p. 6484-6493.

Research output: Contribution to journalArticle

Zhou, B, Su, L, Hu, S, Hu, W, Yip, MLR, Wu, J, Gaur, S, Smith, DL, Yuan, YC, Synold, TW, Horne, D & Yen, Y 2013, 'A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance', Cancer Research, vol. 73, no. 21, pp. 6484-6493. https://doi.org/10.1158/0008-5472.CAN-13-1094
Zhou, Bingsen ; Su, Leila ; Hu, Shuya ; Hu, Weidong ; Yip, M. L Richard ; Wu, Jun ; Gaur, Shikha ; Smith, D. Lynne ; Yuan, Yate Ching ; Synold, Timothy W. ; Horne, David ; Yen, Yun. / A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. In: Cancer Research. 2013 ; Vol. 73, No. 21. pp. 6484-6493.
@article{8f1015abe0ce4470bb3b36fabb19bb89,
title = "A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance",
abstract = "Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A novel ligand-binding pocket on the RNR small subunit (RRM2) near the C-terminal tail was proposed by computer modeling and verified by site-directed mutagenesis and nuclear magnetic resonance (NMR) techniques. A compound targeting this pocket was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule database. By lead optimization, we developed the novel RNR inhibitor COH29 that acted as a potent inhibitor of both recombinant and cellular human RNR enzymes. COH29 overcame hydroxyurea and gemcitabine resistance in cancer cells. It effectively inhibited proliferation of most cell lines in the NCI 60 human cancer panel, most notably ovarian cancer and leukemia, but exerted little effect on normal fibroblasts or endothelial cells. In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle. Site-directed mutagenesis, NMR, and surface plasmon resonance biosensor studies confirmed COH29 binding to the proposed ligand-binding pocket and offered evidence for assembly blockade of the RRM1-RRM2 quaternary structure. Our findings offer preclinical validation of COH29 as a promising new class of RNR inhibitors with a new mechanism of inhibition, with broad potential for improved treatment of human cancer.",
author = "Bingsen Zhou and Leila Su and Shuya Hu and Weidong Hu and Yip, {M. L Richard} and Jun Wu and Shikha Gaur and Smith, {D. Lynne} and Yuan, {Yate Ching} and Synold, {Timothy W.} and David Horne and Yun Yen",
year = "2013",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-13-1094",
language = "English",
volume = "73",
pages = "6484--6493",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance

AU - Zhou, Bingsen

AU - Su, Leila

AU - Hu, Shuya

AU - Hu, Weidong

AU - Yip, M. L Richard

AU - Wu, Jun

AU - Gaur, Shikha

AU - Smith, D. Lynne

AU - Yuan, Yate Ching

AU - Synold, Timothy W.

AU - Horne, David

AU - Yen, Yun

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A novel ligand-binding pocket on the RNR small subunit (RRM2) near the C-terminal tail was proposed by computer modeling and verified by site-directed mutagenesis and nuclear magnetic resonance (NMR) techniques. A compound targeting this pocket was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule database. By lead optimization, we developed the novel RNR inhibitor COH29 that acted as a potent inhibitor of both recombinant and cellular human RNR enzymes. COH29 overcame hydroxyurea and gemcitabine resistance in cancer cells. It effectively inhibited proliferation of most cell lines in the NCI 60 human cancer panel, most notably ovarian cancer and leukemia, but exerted little effect on normal fibroblasts or endothelial cells. In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle. Site-directed mutagenesis, NMR, and surface plasmon resonance biosensor studies confirmed COH29 binding to the proposed ligand-binding pocket and offered evidence for assembly blockade of the RRM1-RRM2 quaternary structure. Our findings offer preclinical validation of COH29 as a promising new class of RNR inhibitors with a new mechanism of inhibition, with broad potential for improved treatment of human cancer.

AB - Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A novel ligand-binding pocket on the RNR small subunit (RRM2) near the C-terminal tail was proposed by computer modeling and verified by site-directed mutagenesis and nuclear magnetic resonance (NMR) techniques. A compound targeting this pocket was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule database. By lead optimization, we developed the novel RNR inhibitor COH29 that acted as a potent inhibitor of both recombinant and cellular human RNR enzymes. COH29 overcame hydroxyurea and gemcitabine resistance in cancer cells. It effectively inhibited proliferation of most cell lines in the NCI 60 human cancer panel, most notably ovarian cancer and leukemia, but exerted little effect on normal fibroblasts or endothelial cells. In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle. Site-directed mutagenesis, NMR, and surface plasmon resonance biosensor studies confirmed COH29 binding to the proposed ligand-binding pocket and offered evidence for assembly blockade of the RRM1-RRM2 quaternary structure. Our findings offer preclinical validation of COH29 as a promising new class of RNR inhibitors with a new mechanism of inhibition, with broad potential for improved treatment of human cancer.

UR - http://www.scopus.com/inward/record.url?scp=84887179562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887179562&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1094

DO - 10.1158/0008-5472.CAN-13-1094

M3 - Article

VL - 73

SP - 6484

EP - 6493

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -